- Home
- AMH vs EXEL Comparison
AMH vs EXEL Comparison
Compare AMH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMH | EXEL |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | 1598 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 11.4B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AMH | EXEL |
|---|---|---|
| Price | $31.89 | $43.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 21 |
| Target Price | $34.92 | ★ $46.50 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $2.69 | $13.61 |
| Revenue Next Year | $2.26 | $13.13 |
| P/E Ratio | $26.59 | ★ $16.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.22 | $33.76 |
| 52 Week High | $39.49 | $48.74 |
Technical Indicators
Market Signals| Indicator | AMH | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 46.95 |
| Support Level | $31.15 | $43.53 |
| Resistance Level | $32.45 | $44.32 |
| Average True Range (ATR) | 0.59 | 1.34 |
| MACD | 0.17 | -0.20 |
| Stochastic Oscillator | 92.49 | 5.54 |
Price Performance
Historical ComparisonAbout AMH American Homes 4 Rent of Beneficial Interest
American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.